1. Home
  2. DBVT vs SSP Comparison

DBVT vs SSP Comparison

Compare DBVT & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • SSP
  • Stock Information
  • Founded
  • DBVT 2002
  • SSP 1878
  • Country
  • DBVT France
  • SSP United States
  • Employees
  • DBVT N/A
  • SSP N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • SSP Broadcasting
  • Sector
  • DBVT Health Care
  • SSP Industrials
  • Exchange
  • DBVT Nasdaq
  • SSP Nasdaq
  • Market Cap
  • DBVT 250.5M
  • SSP 252.6M
  • IPO Year
  • DBVT N/A
  • SSP 1988
  • Fundamental
  • Price
  • DBVT $10.80
  • SSP $3.76
  • Analyst Decision
  • DBVT Buy
  • SSP Strong Buy
  • Analyst Count
  • DBVT 4
  • SSP 1
  • Target Price
  • DBVT $14.81
  • SSP $8.00
  • AVG Volume (30 Days)
  • DBVT 26.3K
  • SSP 970.4K
  • Earning Date
  • DBVT 07-29-2025
  • SSP 08-07-2025
  • Dividend Yield
  • DBVT N/A
  • SSP N/A
  • EPS Growth
  • DBVT N/A
  • SSP N/A
  • EPS
  • DBVT N/A
  • SSP 0.93
  • Revenue
  • DBVT $3,497,000.00
  • SSP $2,472,701,000.00
  • Revenue This Year
  • DBVT $1,700.53
  • SSP N/A
  • Revenue Next Year
  • DBVT $535.67
  • SSP $9.60
  • P/E Ratio
  • DBVT N/A
  • SSP $4.03
  • Revenue Growth
  • DBVT N/A
  • SSP 6.28
  • 52 Week Low
  • DBVT $2.21
  • SSP $1.36
  • 52 Week High
  • DBVT $12.78
  • SSP $4.17
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 58.42
  • SSP 66.07
  • Support Level
  • DBVT $10.53
  • SSP $2.70
  • Resistance Level
  • DBVT $11.33
  • SSP $4.17
  • Average True Range (ATR)
  • DBVT 0.76
  • SSP 0.26
  • MACD
  • DBVT 0.14
  • SSP 0.09
  • Stochastic Oscillator
  • DBVT 65.90
  • SSP 72.11

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: